Bacterin Presents Preclinical Results of an Efficacious Antimicrobial Orthopedic Device Coating BELGRADE, MT--(BUSINESS WIRE)

Bacterin Presents Preclinical Results

of an Efficacious Antimicrobial Orthopedic Device Coating

BELGRADE, MT--(BUSINESS WIRE)- October 22, 2014 -- Bacterin

International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications,

presented preclinical results of a robust and efficacious antimicrobial coating

for orthopedic hardware at the 2014 Orthopaedic Trauma Association (OTA) Annual Meeting.

The coating is intended to address one of the most serious complications

in orthopedic surgery, implant-associated infections. Of the estimated two million fracture-fixation devices implanted annually

in the United States, 100,000 become infected. This leads to not only life threatening complications for the patients but also

places an unnecessary 1.5 billion dollar burden on the healthcare system. To overcome this challenge, researchers at Bacterin have

developed a rifampin- and minocycline-containing coating aimed at inhibiting microbial contamination of the implant that can lead

Mark Schallenberger, MS, the lead research scientist for the

project and presenter of the findings at the OTA Annual Meeting stated, "Our testing has shown that the coating inhibits

infection progression in a rabbit model of pin track infection and significantly aids orthopedic hardware in maintaining anchoring

The antimicrobial coating has not yet received FDA clearance,

but has substantial commercial viability according to Bacterin's Chief Scientific Officer, Gregory Juda, PhD, CTBS, who noted

that, "The results from this preclinical study represent a significant step towards the development of antimicrobial-coated

orthopedic devices. The durability and long-lasting efficacy of this new coating technology makes it broadly applicable to a variety

of orthopedic devices and demonstrates Bacterin's continuing commitment to innovating in the field of orthopedic surgery."

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE

MKT: BONE) develops, manufactures and markets biologic products to domestic and international markets. These products are used

in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot

and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division

develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking

This news release contains certain disclosures that may be deemed

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant

risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer

to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates,"

"intends," "plans," "believes," "estimates," "projects," "forecasts,"

"strategy," "will," "goal," "target," "prospects," "potential," "optimistic,"

"confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical

fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,

and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability

to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the

Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's

ability to remain listed on the NYSE MKT; the Company's ability to develop, market, sell and distribute desirable applications,

products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results;

the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as

and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees

with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact

of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors;

and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form

10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any

forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated

events, except as required by law.